RIPK1 and central nervous system cancer: In a cohort of 81 clinical glioma samples, high Ki67 labeling indices (30–80%) were associated with significantly elevated RIPK1 and MLKL expression compared to low-Ki67 tumors (<30%) (Fig. 2A).